Chapter 5

What the price is, and what sits beneath it

At ₹1,935 Nuvama is valued near ₹35,900 crore (about $3.8bn) — roughly 34x trailing and 29x forward earnings, and 8.7x book against a mid-20s return on equity. Two arm's-length marks sit below that price: the consensus target (₹1,870), and the ~$3.4bn a control buyer, General Atlantic, is reportedly willing to pay for PAG's stake — a deal said to have stalled on the valuation gap the recent rally opened. The premium is real, but it is a sector rating, not a Nuvama outlier.

The economics (Wealth Economics), the owner (Ownership and Governance) and the runway (Industry and Rivals) are now established. This chapter puts a price on them, and asks what a value-minded buyer would have to pay to own the compounding with a cushion.

What the tape says today

Source: price as of 9-Jul-2026 (exchange data); FY26 profit after tax ₹1,040 crore and net worth ₹4,121 crore [1] [2]; multiples derived.

Nuvama earned ₹1,040 crore of consolidated profit in FY26 on ₹3,122 crore of revenue, with net worth of ₹4,121 crore at 31 March 2026 [3] [4]. Against a ₹35,900 crore market capitalisation, that is 34.5x trailing earnings and 8.7x book. On consensus, the forward multiple compresses: nine analysts model earnings per share of ₹67.3 for FY27 and ₹79.9 for FY28, roughly 20% and 19% growth, which puts the stock at 28.7x FY27 and 24.2x FY28. The ratings below reference the same ₹1,935 price against each year's earnings.

Source: FY26 earnings [5]; FY27–FY28 consensus earnings per share (9 analysts); ratios derived.

The 8.7x book value multiple is the number that most rewards scrutiny, because Nuvama is a balance-sheet business — a lender and clearing house wrapped inside a fee franchise (Wealth Economics). A financial is worth book value scaled by how far its return on equity clears its cost of equity. Nuvama's statutory ROE was 25.3% in FY26 (28.1% on the company's operating basis, down from 31.5% in FY25 as capital markets softened) [6]. A mid-20s return does justify a book multiple well above one — but 8.7x is a demanding reading of how long that return holds.

A control buyer marks it lower

The most useful anchor is not a model; it is a transaction. PAG, which owns ~54% of Nuvama, is in advanced talks to sell that stake to General Atlantic for about $1.82bn [7]. That values the whole company near $3.4bn — roughly ₹32,000 crore, or about ₹1,730 a share — some 10% below the ₹35,900 crore the public market assigns. And the negotiation is reportedly held up by exactly this: the gap that opened after Nuvama's stock rallied [8]. A disciplined control buyer, doing full diligence, is presently unwilling to pay the screen price.

Sources: General Atlantic mark derived from the reported ~$1.82bn for ~54% [9]; consensus targets (mean ₹1,870, range ₹1,630–₹2,070) from 9 analysts; price as of 9-Jul-2026.

The sell-side agrees the price is full even without the deal. The mean 12-month target across nine analysts is ₹1,870 — below the ₹1,935 spot — with a ₹1,630 low and ₹2,070 high; Motilal Oswal, a "Buy", carries ₹1,860 [10]. A stock trading above its mean target and above the mark of a well-informed control acquirer is not, by any of those measures, offering a discount.

That reading exists because of how far and fast the stock has moved. On a split-adjusted basis (Nuvama split its shares 1:5 in December 2025 [11]), the price fell to about ₹1,161 at the end of March 2026 and has since risen about two-thirds to ₹1,935 — the run that opened the deal gap.

Source: exchange closing prices, post-split window (Dec 2025 – Jul 2026); split ratio 1:5 effective Dec 2025 [12].

General Atlantic is not a naive party here: it held roughly a 22% stake in 360 ONE (then IIFL Wealth) from 2015, so it knows what Indian wealth-management economics are worth [13]. Its reluctance to chase the rally is a data point a buyer should weigh alongside the multiple.

Mid-pack in an expensive sector

The word "premium" needs a benchmark, and against its listed peers Nuvama is not the expensive one. At 34.5x trailing earnings it sits in the middle of the group — richer than IIFL Capital's pure capital-markets business, close to Angel One and Motilal Oswal, and far below the asset-light distributors Anand Rathi and Prudent, which the market rewards with 55–89x for needing almost no balance sheet.

Sources: market capitalisations from current exchange prices; earnings, net worth and ROE derived from each company's reported FY2026 financials. 360 ONE's ROE is depressed by acquisition goodwill; Motilal Oswal's earnings include treasury and diversified segments, so its multiple is not a clean wealth comparison.

Where Nuvama does look full is book value. Its 8.7x is nearly double the 3.5–5.1x of the other balance-sheet operators — 360 ONE, Motilal Oswal, Angel One, IIFL Capital. Part of that gap is earned: Nuvama's 25.3% ROE is the highest of that balance-sheet cohort, and its earnings mix is tilting toward recurring wealth fees (Wealth Economics). But a doubling of the book multiple asks more of ROE durability than a mid-20s return, drifting down from 31.5%, comfortably supplies.

Sources: ROE and price/book derived from reported FY2026 financials and current market prices; bubble size is market capitalisation.

What 34x embeds

A balance-sheet financial is worth roughly (ROE − g) / (COE − g) times book, where g is sustainable growth and COE the cost of equity. Hold Nuvama's ROE at 25% and put the cost of equity near 14% — a reasonable level for a mid-cap Indian financial with cyclical earnings — and 8.7x book can only be reconciled by embedding perpetual growth close to that cost of equity, i.e. high-teens compounding that never fades. That is not impossible in a sunrise industry (Industry and Rivals), but it is the assumption the multiple rests on, and it is the one a drawdown would test.

The more useful version of the same arithmetic is the downside. The table below reads off the "fair" book multiple if the through-cycle settling point for ROE and growth turns out lower than today's — the scenario a value buyer underwrites against.

Source: derived, single-stage residual-income model at a 14% cost of equity; illustrative, not a forecast. It deliberately excludes the near-term growth premium, so it reads as a downside floor rather than a fair value.

The gap between 8.7x today and 2–5x in these settled-state scenarios is the growth premium the market is paying for — the value of Nuvama compounding at 20%-plus for years before the return fades. On forward earnings the same premium reads as a PEG near 1.5x (28.7x FY27 earnings against ~20% growth): not cheap, not extreme, and entirely dependent on the growth persisting. Dividends do little to close the gap — Nuvama pays out about 49% of operating profit [14], but at this price that is a yield near 1.5%. The return case is capital appreciation from compounding, not income.

Where a cushion would appear

Three independent marks — the consensus target, the control-buyer valuation, and the settled-state book multiples — all sit below the ₹1,935 price, and the near-term rating leaves little room for the cyclical half of earnings to disappoint (What Nuvama Is). On the reader's own terms, a margin of safety is not present at today's price; it would begin to appear nearer the ₹1,600–₹1,730 zone where the control buyer and the street low converge, and would be clear only a further step below that — roughly where the stock traded through the first quarter of 2026.

That read has a real counter. Nuvama's compounding has been fast and its mix is improving: the recurring wealth engine grows in the 20–30s, Asset Services posted record profit through a weak capital-markets year, and a 25% ROE on a widening fee base can grow into a high multiple rather than de-rate to it (Wealth Economics). If FY27–FY28 earnings land near the ₹67–₹80 consensus and the wealth mix keeps shifting, today's 29x forward becomes 24x on FY28 and the premium quietly amortises. What would change the read in the buyer's favour is concrete and checkable: the General Atlantic deal closing at or above the current price (a validation, not a discount), consensus FY27 earnings revised up rather than down, or a market drawdown resetting the entry point. What would harden the caution is the mirror image — the deal repriced or abandoned on the valuation gap, ROE continuing its drift below the mid-20s, or the transactional and broking base that still dominates client assets dragging blended economics as the cycle turns.